A one-fifth dose of Bavarian Nordic’s mpox vaccine Jynneos can elicit a similar antibody response as its standard-dose regimen, according to findings presented Saturday at the European Society of ...
Bavarian Nordic A/S, a fully integrated vaccine company, announced that Jynneos, the only FDA-approved mpox vaccine, is now commercially available in the US, marking a significant expansion for access ...
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS ...
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a ...
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS ...
Bavarian Nordic has an annual production capacity of 30 million doses. According to the drugmaker's Vice President Sass Sørensen, the vaccine is “in stock in numerous countries” and can be ...
A new production facility under construction near Grand Rapids will boost Grand River Aseptic Manufacturing Inc.’s capacity to accommodate the company’s continued high growth rate.
People wait in line for a monkeypox vaccine at one of the few Chicago locations distributing the shot on Monday, July 25, 2022. With vaccine in extremely short supply, this clinic can currently only ...
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS ®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a ...
Bavarian Nordic will submit additional data over the coming months, aiming to complete the BLA submission before the end of the first half of 2024 to support a potential FDA approval of the vaccine in ...